Annals of Internal Medicine · 2020 · 111 citations · 46 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyDiabetologyGeneral Internal MedicineDiabetes ControlDiabetes ManagementDiabetes MellitusDiabetes PharmacotherapyGlycemic ControlInsulin TherapyCombination Therapy With InsulinGlycemic TargetsGuidanceLow Glycemic Index TreatmentOral Combination TherapyType 2 Diabetes Mellitus TreatmentType 2 Diabetes PharmacotherapyType 2 Diabetes Treatment
DESCRIPTION: The American Diabetes Association (ADA) updates the Standards of Medical Care in Diabetes annually to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of diabetes. METHODS: To develop the 2020 Standards, the ADA Professional Practice Committee, comprising physicians, adult and pediatric endocrinologists, diabetes educators, registered dietitians, epidemiologists, pharmacists, and public health experts, continuously searched MEDLINE (English language only) from 15 October 2018 through August-September 2019 for pertinent studies, including high-quality trials that addressed pharmacologic management of type 2 diabetes. The committee selected and reviewed the studies, developed the recommendations, and solicited feedback from the larger clinical community. RECOMMENDATIONS: This synopsis focuses on guidance relating to the pharmacologic treatment of adults with type 2 diabetes. Recommendations address oral and noninsulin injectable therapies, insulin treatment, and combination injectable therapies. Results of recent large trials with cardiovascular and renal outcomes are emphasized.
46
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Rury R. Holman, Sanjoy K. Paul, M. Angelyn Bethel et al. · New England Journal of Medicine · 2008 · 7.8K citations · Full text
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine · 2018 · 6.3K citations · Full text